Further clinical interpretation and implications of KEYNOTE-048 findings
- 1 August 2020
- journal article
- letter
- Published by Elsevier in The Lancet
- Vol. 396 (10248) , 379
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaAnnals of Oncology, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016